Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02 Article

Chen, Huanwen, Kuhn, John, Lamborn, Kathleen R et al. Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02 . 2(1), 10.1093/noajnl/vdaa124

cited authors

  • Chen, Huanwen; Kuhn, John; Lamborn, Kathleen R; Abrey, Lauren E; DeAngelis, Lisa M; Lieberman, Frank; Robins, H Ian; Chang, Susan M; Yung, WK Alfred; Drappatz, Jan; Mehta, Minesh P; Levin, Victor A; Aldape, Kenneth; Dancey, Janet E; Wright, John J; Prados, Michael D; Cloughesy, Timothy F; Wen, Patrick Y; Gilbert, Mark R

authors

keywords

  • BRAIN-TUMOR CONSORTIUM
  • Clinical Neurology
  • DOUBLE-BLIND
  • II TRIAL
  • JAPANESE PATIENTS
  • LUNG-CANCER
  • Life Sciences & Biomedicine
  • MALIGNANT GLIOMAS
  • MULTIFORME
  • Neurosciences & Neurology
  • Oncology
  • RADIATION-THERAPY
  • Science & Technology
  • TEMOZOLOMIDE
  • TEMSIROLIMUS
  • erlotinib
  • glioblastoma
  • molecular therapy
  • novel trial design
  • sorafenib

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS

volume

  • 2

issue

  • 1